ArticlePloS one2026
Prevalence of multiple morbidities and cancers in individuals with Down syndrome: A matched descriptive study using linked electronic health record data.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDown syndrome is associated with the development of multiple morbidities throughout the life course, yet comprehensive data on its relative burden remains limited. This descriptive, matched, retrospective cohort study aimed to assess the 20-year period prevalence of morbidities and cancers in adults and children with Down syndrome.
methodsWe analysed electronic health record data from January 1998 to December 2017, matching individuals with Down syndrome to up to five matched controls. Period prevalence and odds ratios (OR) were calculated for 30 morbidities and 24 cancers.
resultsThis study included 4,648 individuals with Down syndrome (32,920 person-years) and 23,238 matched controls (236,883 person-years). Most morbidities had a significantly higher period prevalence in individuals with Down syndrome, including hypothyroidism (30.4%), congenital cardiac disease (27.8%), and epilepsy (21.9%). We found an increased comparative risk of autism (OR 7.5, 95% CI 6.4-8.0), chronic kidney disease (OR 2.4, 95% CI 2.1-2.8) and inflammatory bowel disease (OR 2.5, 95% CI 2.2-2.8). Individuals with Down syndrome also had a significantly higher period prevalence of leukaemia and testicular cancer. Conversely, most solid tumours were less prevalent in individuals with Down syndrome.
conclusionsThis study presents findings from one of the largest described cohorts of individuals with Down syndrome, contributing to an understanding of the comparative prevalence of multiple comorbidities and cancers among both adults and children with Down syndrome. These findings support prioritising surveillance for a range of conditions such as hypothyroidism and childhood leukaemia and may justify de-emphasising routine screening for several solid tumours in Down syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.